ライフサイエンスコーパス: pulmonary nodule

1 choices about whether to perform biopsy of a pulmonary nodule.

2 s made by fine-needle aspiration biopsy of a pulmonary nodule.

3 apulmonary malignant neoplasm and a solitary pulmonary nodule.

4 ction, bronchiectasis, mucus plugging, and a pulmonary nodule.

5 clinic with an incidental or screen-detected pulmonary nodule.

6 ssing values for patients without a dominant pulmonary nodule.

7 here was a nonspecific 3-mm right lower lobe pulmonary nodule.

8 th chest CT in order to detect indeterminate pulmonary nodules.

9 uld be used to measure the volumes of larger pulmonary nodules.

10 mprovement in the detection of subcentimeter pulmonary nodules.

11 n, seven women; age range, 40-75 years) with pulmonary nodules.

12 section thickness, and 0.6-mm interval) for pulmonary nodules.

13 ssification of benign and malignant solitary pulmonary nodules.

14 specificity for histopathologic diagnosis of pulmonary nodules.

15 eful but expensive test to diagnose solitary pulmonary nodules.

16 been successfully used to investigate single pulmonary nodules.

17 widespread application in the assessment of pulmonary nodules.

18 distinction of benign and malignant solitary pulmonary nodules.

19 gram that indicates areas that may represent pulmonary nodules.

20 experienced radiologists for the presence of pulmonary nodules.

21 nt peptide reduced the number of established pulmonary nodules.

22 tecting malignancy in indeterminate solitary pulmonary nodules.

23 with radiographically indeterminate solitary pulmonary nodules.

24 rlier for similar symptoms revealed multiple pulmonary nodules.

25 filing could provide a strategy for managing pulmonary nodules.

26 as a precision tool for future management of pulmonary nodules.

27 rker placement for preoperative planning for pulmonary nodules.

28 nation to estimate 3-year malignancy risk of pulmonary nodules.

29 lly detected, and bronchoscopically biopsied pulmonary nodules.

30 y, and 99.1% area under curve in classifying pulmonary nodules.

31 dy cohort included 198 participants with 221 pulmonary nodules.

32 gists in the multidisciplinary management of pulmonary nodules.

33 cepted as the preferred method for detecting pulmonary nodules.

34 lity at distinguishing benign from malignant pulmonary nodules.

35 g methods in the evaluation and follow-up of pulmonary nodules.

36 ing (IMI) can improve detection of malignant pulmonary nodules.

37 performed in 116 patients for assessment of pulmonary nodules.

38 ance compared with routine dose in depicting pulmonary nodules.

39 the chest showed a mixed response among the pulmonary nodules.

40 dentified multiple nonspecific subcentimeter pulmonary nodules.

41 mprove the quality of care for patients with pulmonary nodules.

42 standardized uptake value (SUV), and size of pulmonary nodules.

43 ction of appreciable number of indeterminate pulmonary nodules.

44 he management of patients with indeterminate pulmonary nodules.

45 radiographs, 20 with a solitary uncalcified pulmonary nodule 1-2 cm in diameter, and 20 with fibroti

46 TSC/LAM had higher frequency of noncalcified pulmonary nodules (12% vs 1%, P<.01), hepatic (33% vs 2%

47 arched for data on gross specimens revealing pulmonary nodules 3 cm or smaller.

48 Spherical and lobulated pulmonary nodules 3-15 mm in diameter were placed in a c

49 her HRCT findings were: consolidation (63%), pulmonary nodules (31.4%), mediastinal and/or hilar lymp

50 high sensitivity for the detection of small pulmonary nodules (4-8 mm) and outperformed a three-dime

51 utine dose in the detection of indeterminate pulmonary nodules 5 mm or greater.

52 Although less frequent, solitary pulmonary nodule (5.2%-14.4%), enlarged lymph nodes (3.7

53 Although less frequent, solitary pulmonary nodule (5.2-14.4%), enlarged lymph nodes (3.7-

54 ures to quantify the shape complexity of the pulmonary nodules, 7th-Order Markov Gibbs Random Field b

55 The treatment of an individual with a solid pulmonary nodule 8 mm or larger is based on the estimate

56 Multiple pulmonary nodules (96%) were the most common CT findings

57 prospective cohort study was performed at a pulmonary nodule and lung cancer screening clinic from O

58 Patients referred to the pulmonary nodule and lung cancer screening clinic with a

59 he linear caliper measurements overestimated pulmonary nodule and surface nodule size by a median of

60 Characteristics of pulmonary nodules and additional findings were tabulated

61 e superior to helical scans to help identify pulmonary nodules and characterize them as peribronchova

62 melioidosis in the differential diagnosis of pulmonary nodules and chronic melioidosis in the differe

63 creased diagnostic accuracy for detection of pulmonary nodules and fibrosis.

64 esection, IMI was utilized to evaluate known pulmonary nodules and identify synchronous lesions.

65 SGM-101 localization to pulmonary nodules and its correlation with CEACAM5 glyco

66 te noninvasive imaging test for diagnosis of pulmonary nodules and larger mass lesions, although few

67 study was to evaluate the detection rate of pulmonary nodules and lung cancer in the initial, helica

68 the differentiation of malignant and benign pulmonary nodules and masses.

69 Pulmonary nodules and nodular infiltrates occur frequent

70 However, accurately diagnosing invasive pulmonary nodules and predicting tumor invasiveness rema

71 the technique for hook-wire localization of pulmonary nodules and the keys to ensuring the best resu

72 The frequency of solid and part-solid pulmonary nodules and the lung cancer diagnoses using an

73 The frequency of solid and part-solid pulmonary nodules and the rate of lung cancer diagnosis

74 Its utility for the diagnosis of peripheral pulmonary nodules and therapeutic treatments besides asp

75 omputed tomography scans for the presence of pulmonary nodules and to record their findings on a stan

76 Patients who had pulmonary nodules and underwent a transthoracic needle b

77 e nodule was a 5-mm-or-greater indeterminate pulmonary nodule, and graded image quality.

78 escribe the spatial non-homogeneities in the pulmonary nodule, and volumetric features (size) of pulm

79 spective CT scans from 467 patients with 727 pulmonary nodules, and breath samples from 504 patients

80 ning with low-dose CT, incidentally detected pulmonary nodules, and nodules deemed suspicious enough

81 nt in characterizing tumors, lung perfusion, pulmonary nodules, and the tumor response to new treatme

82 Indeterminate pulmonary nodules are a common radiographic finding and

83 Incidental pulmonary nodules are an increasingly common consequence

84 Pulmonary nodules are categorized as small solid (<8 mm)

85 Pulmonary nodules are common incidental findings, but in

86 Solitary pulmonary nodules are common, often incidental findings

87 Because pulmonary nodules are found in up to 25% of patients und

88 est computed tomography scans, indeterminate pulmonary nodules are frequently detected as an incident

89 Pulmonary nodules are frequently detected during diagnos

90 Pulmonary nodules are frequently detected radiological a

91 Pulmonary nodules are identified in approximately 1.6 mi

92 Pulmonary nodules are identified in approximately 1.6 mi

93 Each year, millions of pulmonary nodules are identified incidentally or through

94 In addition, millions of pulmonary nodules are incidentally detected annually in

95 Part-solid pulmonary nodules are managed according to the size of t

96 Many pulmonary nodules are nonspecific, and many might not be

97 In these patients, pulmonary nodules are not always metastases, so the corr

98 Nearly one-third of solitary pulmonary nodules are radiographically indeterminate for

99 Using patients with pulmonary nodules as a study model, we hypothesized that

100 This proof-of-concept study analyzes pulmonary nodules as a test case, but the results may be

101 ischner Society guidelines for management of pulmonary nodules as solid, part solid with a solid comp

102 One patient remains alive with stable pulmonary nodules at 28+ months.

103 ccurate estimation of the malignancy risk of pulmonary nodules at chest CT is crucial for optimizing

104 In patients with AIDS who have multiple pulmonary nodules at CT, nodule size and distribution ar

105 Our study demonstrated that indeterminate pulmonary nodules at diagnosis do not affect outcome in

106 age patients with RMS who have indeterminate pulmonary nodules at diagnosis.

107 and therapeutic approaches in patients with pulmonary nodules at risk for lung cancer.

108 ely distinguishes invasive from non-invasive pulmonary nodules (AUC = 0.952), outperforming establish

109 es suggest the need for better predictors of pulmonary nodules being malignant or benign, so as to re

110 from 139 individuals with clinically evident pulmonary nodules (benign and malignant), as well as ten

111 pective immunohistochemical examination of a pulmonary nodule, biopsied 3 years prior, was immunoreac

112 CBCT guidance in pulmonary nodule biopsy provided higher diagnostic sensi

113 thyroid, myocardium) and malignant lesions (pulmonary nodules, bone lesions); the regression line wa

114 n patients undergoing biopsies of peripheral pulmonary nodules, but the relative diagnostic accuracy

115 Analysis of a spectrum of subsolid pulmonary nodules by single-cell RNA sequencing provides

116 distinguishing between benign and malignant pulmonary nodules by use of features extracted from CT,

117 tion of the pneumonia often leaves calcified pulmonary nodules, calcified mediastinal lymph nodes, or

118 Optimal treatment of an individual with a pulmonary nodule can lead to early detection of cancer w

119 Transthoracic needle biopsy of small pulmonary nodules can produce diagnostic yields comparab

120 Pulmonary nodule characterization is currently being red

121 In this study, we have developed a pulmonary nodule classifier (PNC) using RNA from whole b

122 minimally invasive and clinically practical pulmonary nodule classifier that has good diagnostic abi

123 was no difference in diagnostic accuracy for pulmonary nodules compared with lesions of any size (P =

124 Background Subsolid pulmonary nodules, comprising pure ground-glass nodules

125 t surgery, an attempt was made to excise any pulmonary nodule considered suspicious for carcinoma at

126 An independent set of resected pulmonary nodules consisting of both adenocarcinomas and

127 nary nocardiosis presents mainly as multiple pulmonary nodules, consolidations, and cavity in both im

128 Upon detection of a pulmonary nodule (day 67 p.t.), a bronchoalveolar lavage

129 iagnostic CT was performed in 747 suspicious pulmonary nodules detected at low-dose CT screening (17

130 iologists, for malignancy risk estimation of pulmonary nodules detected at screening CT.

131 algorithm for malignancy risk estimation of pulmonary nodules detected at screening CT.

132 cer and risk stratification in patients with pulmonary nodules detected by CT.

133 m developed to assess the malignancy risk of pulmonary nodules detected on low-dose CT scans in lung

134 ve a negligible impact on improving solitary pulmonary nodule detection (6 to 20 mm).

135 pack-years were positively associated with a pulmonary nodule detection (p = 0.037 and p = 0.044, res

136 ging, and conventional chest radiography for pulmonary nodule detection and management.

137 Specifically, pulmonary nodule detection had an AUC performance ratio

138 inputs, emphysema, cardiomegaly, hernia, and pulmonary nodule detection had the highest fractional im

139 An automated pulmonary nodule detection program that takes advantage

140 Performance of an automated pulmonary nodule detection program was evaluated on mult

141 d to evaluate the impact of AI assistance on pulmonary nodule detection rates among radiology residen

142 The number of pulmonary nodules discovered incidentally or through scr

143 were treated identically to patients without pulmonary nodules, enabling us to compare event-free sur

144 ond highest for lesion detectability in most pulmonary nodule evaluation cases.

145 tee with expertise in lung cancer screening, pulmonary nodule evaluation, and implementation science.

146 nt advocates reviewed available evidence for pulmonary nodule evaluation, characterized six focus are

147 s on imaging and 249 patients (78.8%) had no pulmonary nodules evident at diagnosis.

148 Background Pulmonary nodule features have been used to differentiat

149 vis (not shown) was unremarkable, showing no pulmonary nodules, features of primary malignancy, or ly

150 men, and pelvis was unremarkable, showing no pulmonary nodules, features of primary malignancy, or ly

151 rlier for similar symptoms revealed multiple pulmonary nodules (Fig 1).

152 Chest radiographs revealed lymphadenopathy, pulmonary nodules, focal consolidation, reticular opacit

153 s (n = 8) were assessed for lymphadenopathy, pulmonary nodules, focal consolidation, reticular or gra

154 Pulmonary nodule follow-up is the most common cause for

155 tant history of extensive rabbit contact and pulmonary nodules for 6 years developed empyema.

156 One hundred fifteen pulmonary nodules for which two thin-section small-field

157 solid, intermediate-sized, intraparenchymal pulmonary nodules found at baseline screening for lung c

158 osine kinase Syk in TSC2-deficient cells and pulmonary nodules from lymphangioleiomyomatosis patients

159 Analysis of multifocal pulmonary nodules from the same patients reveal evidence

160 tic patients with histopathologically proven pulmonary nodules greater than 15 mm, the mentioned lesi

161 ning and/or follow-up of patients with solid pulmonary nodules (> 3 mm) and consolidation.

162 Ground-glass pulmonary nodules have a probability of malignancy of 10

163 contrast agent (OTL38) can improve malignant pulmonary nodule identification when combined with PET.

164 Low-dose CT is acceptable for pulmonary nodule identification, making it suitable for

165 At least 95% of all pulmonary nodules identified are benign, most often gran

166 IMI identified 56 of 59 (94.9%) malignant pulmonary nodules identified by preoperative imaging.

167 ULDCT depicted pulmonary nodules in 1045 (38%) participants, with an av

168 differentiate benign and malignant solitary pulmonary nodules in 61 patients with radiographically i

169 to discriminate between benign and malignant pulmonary nodules in a prospective, multicenter trial.

170 o cases in patients presenting with multiple pulmonary nodules in a setting of immunocompromise and o

171 CT most commonly demonstrated pulmonary nodules in immunocompetent patients with pulmo

172 ate, noninvasive method for the diagnosis of pulmonary nodules in patients with non-small cell lung c

173 oriented approach to incidentally identified pulmonary nodules in the last decade has led to populati

174 tratified by the route of detection of their pulmonary nodules (incidental vs screen detected).

175 thma, chronic obstructive pulmonary disease, pulmonary nodules, interstitial lung disease, hepatic hy

176 cluded individuals enrolled in an incidental pulmonary nodule (IPN) program with non-screening-detect

177 there is still a high rate of indeterminate pulmonary nodules (IPN) of unknown risk.

178 Rationale: Patients with indeterminate pulmonary nodules (IPNs) at risk of cancer undergo high

179 Rationale: The management of indeterminate pulmonary nodules (IPNs) remains challenging, resulting

180 sessment of malignancy risk in indeterminate pulmonary nodules (IPNs).

181 A disappearing or persistent solid pulmonary nodule is a neglected clinical entity that sti

182 an alternative approach for determining if a pulmonary nodule is a primary lung adenocarcinoma.

183 The imaging evaluation of a solitary pulmonary nodule is complex.

184 e some general features that indicate that a pulmonary nodule is likely to be a metastasis, sometimes

185 approach to the management of patients with pulmonary nodules is evolving as technologies develop.

186 Percutaneous localization of pulmonary nodules is key for two reasons: it enables the

187 The investigation of pulmonary nodules is time-consuming and often leads to p

188 Small pulmonary nodules < 7 mm were not considered to require

189 spectively collected 92 consecutive cases of pulmonary nodules (<3 cm) in patients who underwent both

190 at eight centers enrolling participants with pulmonary nodules (<3 cm; without computed tomography [C

191 pted clinical tool in patients with solitary pulmonary nodules, lung cancer, colorectal cancer, melan

192 state cancer on MRI scans, and prediction of pulmonary nodule malignancy on low-dose CT images were a

193 The pulmonary nodule malignancy prediction algorithm was com

194 For pulmonary nodule malignancy prediction, accuracy of AI w

195 agnosis improved estimation of indeterminate pulmonary nodule malignancy risk on chest CT scans and i

196 to systematically train an AI algorithm for pulmonary nodule malignancy risk prediction across vario

197 onstrated excellent performance in assessing pulmonary nodule malignancy risk, achieving clinical lev

198 Supervised Learning, Lung Cancer Screening, Pulmonary Nodule Malignancy Risk, Deep Learning, Pulmona

199 learning algorithms to develop an integrated pulmonary nodule management platform.

200 onary Nodule Malignancy Risk, Deep Learning, Pulmonary Nodule Management Supplemental material is ava

201 dentification and confirmation of persistent pulmonary nodules, masses, or consolidations on cross-se

202 Seventy-eight pulmonary nodules (mean diameter, 1.5 cm; range, 0.5-3.5

203 Results There were 66 indeterminate pulmonary nodules (mean size, 8.6 mm +/- 3.4 [standard d

204 an intermediate-risk or high-risk peripheral pulmonary nodule measuring 10 to 30 mm in diameter to un

205 needle biopsy among patients with peripheral pulmonary nodules measuring 10 to 30 mm.

206 a good overall performance for detection of pulmonary nodules measuring 4 mm or larger and almost eq

207 who underwent CT-guided biopsy of subpleural pulmonary nodules measuring up to 2 cm in diameter were

208 atients with thoracic lesions, predominately pulmonary nodules, measuring 0.7-5.2 cm (mean, 1.6 cm) u

209 of malignancy associated with subcentimeter pulmonary nodules (micronodules) in patients with malign

210 infection presenting as multiple spiculated, pulmonary nodules mimicking cancer for which the patient

211 We micro-dissect malignant pulmonary nodules (MPNs) into paired pre-invasive and in

212 d intrathoracic PTLD manifesting as multiple pulmonary nodules (n = 10), a solitary nodule (n = 3), a

213 abnormal findings on the chest CT scan were pulmonary nodules (n = 14), followed by cysts (n = 6) an

214 The most common CT finding was pulmonary nodules (n = 9).

215 infection demonstrated key differences with pulmonary nodules observed in 39.61% in non-DCM, 13.64%

216 infection demonstrated key differences, with pulmonary nodules observed in 39.61% of the non-DCM grou

217 icantly strong correlation between SUVmax of pulmonary nodules obtained with PET/CT and that obtained

218 ex was applied to assess the malignancies of pulmonary nodules of 109 participants (original + contro

219 h resolution CT (HRCT) was performed for 118 pulmonary nodules of the adenocarcinoma spectrum surgica

220 ly predict the presence of EGFR mutations in pulmonary nodules of the adenocarcinoma spectrum.

221 Background Diagnostic workup of small pulmonary nodules often requires follow-up CT scans to c

222 luded; 67 patients (21.2%) had indeterminate pulmonary nodules on imaging and 249 patients (78.8%) ha

223 eripheral blood eosinophilia, sinusitis, and pulmonary nodules on radiographic evaluation.

224 Six patients had pulmonary nodules, one of which was calcified at chest r

225 The carcinomas most commonly manifest as a pulmonary nodule or mass on chest radiographs, with more

226 tial treatment recommendation for suspicious pulmonary nodules or lung cancer.

227 common findings resulting in follow-up were pulmonary nodules or masses (559 of 1558, 35.9%), other

228 ions; enrolled at least 10 participants with pulmonary nodules or masses, including at least 5 partic

229 on-screening-detected, potentially malignant pulmonary nodules, or enrolled in a LCS program from 201

230 n Society of Clinical Oncology measured five pulmonary nodule phantoms that ranged in size from 1.76

231 ther findings assessed included noncalcified pulmonary nodules, pleural effusion, thoracic duct dilat

232 r annual CT lung screening were analysed for pulmonary nodules (PN) detection and secondary lung canc

233 Pulmonary nodules (PNs) are often detected incidentally

234 rted major NCFs were portal vein thrombosis, pulmonary nodule, pulmonary embolism, and liver nodule.

235 In detecting pulmonary nodules, radiologists perform comparably with

236 thms in discriminating malignant from benign pulmonary nodules ranging from 6-20 mm using just 41 dia

237 Three thoracic radiologists circled pulmonary nodules, rating confidence that the nodule was

238 origenesis, we evaluated surgically resected pulmonary nodules representing the spectrum of early lun

239 cohort, 1 in 4 patients with screen-detected pulmonary nodules requiring intervention were treated wi

240 ecluded surgical exploration with suspicious pulmonary nodules requiring surgical biopsy were include

241 findings or as major abnormalities, such as pulmonary nodules, requiring further diagnostic evaluati

242 A single pulmonary nodule resected at VATS was more likely to be

243 omplete responses (RCRs) and slow incomplete pulmonary nodule responses (SIRs).

244 All adult patients with a new, noncalcified pulmonary nodule seen on chest radiograph.

245 a considerable portion of incidentally found pulmonary nodules seen at high-resolution CT.

246 Resolving pulmonary nodules share CT features with malignant nodul

247 The treatment of an individual with a pulmonary nodule should be guided by the probability tha

248 is suggests that management of patients with pulmonary nodules should begin with estimating the prete

249 l loop planimeter measurements overestimated pulmonary nodule size and surface nodule size by a media

250 e and is based on conventional criteria (eg, pulmonary nodules, skeletal metastases, and lymphadenopa

251 6 months were reviewed to find patients with pulmonary nodules smaller than 1 cm in long axis for whi

252 The solitary pulmonary nodule (SPN) has always been a diagnostic chal

253 The solitary pulmonary nodule (SPN) is a common radiologic abnormalit

254 and CT in the characterization of a solitary pulmonary nodule (SPN).

255 ents who present with indeterminate solitary pulmonary nodules (SPN).

256 Solitary pulmonary nodules (SPNs) are commonly identified by ches

257 cancer worldwide, usually presents as solid pulmonary nodules (SPNs) on early diagnostic images.

258 PET are widely used to characterize solitary pulmonary nodules (SPNs).

259 ents (aged 65 +/- 14 y) underwent PET/CT for pulmonary nodule staging (mean, 11 +/- 7 mm; range, 5-18

260 on also resulted in significant reduction of pulmonary nodules, suggesting that regulation of invasio

261 Eighteen pulmonary nodules suspicious for lung cancer were found

262 recommended for the noninvasive diagnosis of pulmonary nodules suspicious for lung cancer.

263 tive at estimating 3-year malignancy risk of pulmonary nodules than established models that only use

264 nostic yield in the assessment of peripheral pulmonary nodules than navigational bronchoscopy with a

265 able to differentiate benign from malignant pulmonary nodules than were the CAD schemes based on PET

266 ker with a prior transbronchial biopsy for a pulmonary nodule that was negative for malignancy or inf

267 ermined the incidence of malignancy among 81 pulmonary nodules that were sampled at biopsy within 3 w

268 These patients had pulmonary nodules that were surgically resected and whic

269 tic evaluation of an incidentally discovered pulmonary nodule; the 2 conjuncts were the probabilities

270 From raw CT data in 10 patients with pulmonary nodules, three sets of CT images were reconstr

271 6-88 y) with 38 known or suspected malignant pulmonary nodules underwent PET of the thorax at 2 time

272 Three-dimensional methods for quantifying pulmonary nodule volume at computed tomography (CT) and

273 A solitary pulmonary nodule was found in the right middle lobe whic

274 vestigation of screen-detected non-calcified pulmonary nodules was guided by ELCAP recommendations, w

275 The incidence of pulmonary nodules was increased in the cyclosporine-trea

276 The CT-guided fiducial marker placement of pulmonary nodules was safe, effective, and resulted in a

277 y specimens from patients with indeterminant pulmonary nodules, we show that assessment of intermolec

278 e surgery, 30 patients with an indeterminate pulmonary nodule were intravenously administered a folat

279 ry nodule, and volumetric features (size) of pulmonary nodules were calculated from CT images.

280 In seven patients, discrete, 1-2-cm pulmonary nodules were detected at CT.

281 Pulmonary nodules were detected in 921 (46%) subjects.

282 Pulmonary nodules were found in about one-third of patie

283 Reference indeterminate pulmonary nodules were identified by two nonreader thora

284 fter baseline CT scanning, 2,832 uncalcified pulmonary nodules were identified in 1,049 participants

285 review board-approved prospective study, 82 pulmonary nodules were identified in eight patients with

286 sed up to 5 days before index operation, and pulmonary nodules were imaged using a near-infrared came

287 Pulmonary nodules were monitored for 2 years with follow

288 Pulmonary nodules were more common in women with cysts (

289 rate, and sites of recurrence and number of pulmonary nodules were recorded.

290 racic computed tomography (CT) for suspected pulmonary nodules were recruited to undergo both digital

291 tained in 60 patients with AIDS and multiple pulmonary nodules were reviewed retrospectively by two t

292 Radiologically indeterminate 7-30-mm pulmonary nodules were studied in 107 patients with mali

293 RMS 2005 Study, patients with indeterminate pulmonary nodules were treated identically to patients w

294 t PTNB can be safely used for the work-up of pulmonary nodules when there is a suspicion of lung canc

295 aximum standardized uptake value (SUVmax) in pulmonary nodules with a diameter of at least 1 cm was c

296 take on PET and scattered diffuse 1- to 2-mm pulmonary nodules with ground-glass opacities ( Fig 1 ).

297 Fifty patients with pulmonary nodules with imaging features suspicious for m

298 of abnormalities detected and classified as pulmonary nodules, with differences of up to more than t

299 cal thinning and multiple bilateral PET-avid pulmonary nodules, with the largest in the left upper lu

300 stic performance of MRI for the detection of pulmonary nodules, with use of CT as the reference stand